Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alchemia Limited announces in-licensing of fak inhibitors from cancer research technology


Wednesday, 5 Mar 2014 12:00am EST 

Alchemia:Announced the in-licensing of two early-stage novel anticancer drug candidates from Cancer Research Technology (CRT).The preclinical Focal Adhesion Kinase inhibitors originate from the Australian Cancer Therapeutics CRC (CTx).Says it will be evaluated by Alchemia in various cancer and cancer stem cell models prior to initiation of formal preclinical and clinical development.The two licenses include fees, milestones and royalty payments.Says further terms are not disclosed. 

Company Quote

0.086
 --
19 Dec 2014